Metformin

Generic Name
Metformin
Brand Names
Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
Drug Type
Small Molecule
Chemical Formula
C4H11N5
CAS Number
657-24-9
Unique Ingredient Identifier
9100L32L2N
Background

Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
...

Indication

Metformin immediate-release formulations

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.

Metformin extended-release tablet (XR)
...

Associated Conditions
Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
Associated Therapies
-

A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood

First Posted Date
2024-07-17
Last Posted Date
2024-12-20
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
32
Registration Number
NCT06504862
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Serum Biomarker Levels Improvement in Poly Cystic Ovarian Syndrome: Impact of Metformin Compared to Healthy Controls

Not Applicable
Recruiting
Conditions
Interventions
First Posted Date
2024-06-28
Last Posted Date
2024-06-28
Lead Sponsor
Aga Khan University
Target Recruit Count
110
Registration Number
NCT06479434
Locations
🇵🇰

DBBS, Karachi, Sind, Pakistan

Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)

Phase 2
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-06-18
Last Posted Date
2024-10-28
Lead Sponsor
State University of New York at Buffalo
Target Recruit Count
30
Registration Number
NCT06463743

Preventing T2DM After GDM With Immediate Postpartum Screening

First Posted Date
2024-06-13
Last Posted Date
2024-11-15
Lead Sponsor
University of Massachusetts, Worcester
Target Recruit Count
116
Registration Number
NCT06457139
Locations
🇺🇸

University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States

Comparing the Effect of Metformin vs. Pep2dia as an Adjunct to Letrozole on Ovulation Induction and Pregnancy Outcomes in Overweight Women With PCOS

Early Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2024-06-11
Last Posted Date
2024-08-26
Lead Sponsor
Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy
Target Recruit Count
100
Registration Number
NCT06452511
Locations
🇪🇬

Al-Hussein University Hospital, Cairo, Egypt

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

First Posted Date
2024-06-06
Last Posted Date
2024-08-09
Lead Sponsor
Ohio State University
Target Recruit Count
1572
Registration Number
NCT06445946
Locations
🇺🇸

University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States

🇺🇸

University of Alabama, Tuscaloosa, Alabama, United States

🇺🇸

Wake Forest University, Winston-Salem, North Carolina, United States

and more 17 locations

Prevention of Progression of Prediabetes, Obesity and CV Risk

First Posted Date
2024-06-06
Last Posted Date
2024-10-17
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
64
Registration Number
NCT06446531
Locations
🇺🇸

University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

Effects of First-Line Oral Hypoglycemics in Bone Markers of Treatment Naïve Saudi Adults With Type 2 Diabetes

Phase 4
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-06-03
Last Posted Date
2024-06-03
Lead Sponsor
King Saud University
Target Recruit Count
111
Registration Number
NCT06439758
© Copyright 2024. All Rights Reserved by MedPath